5'-O-(2-Hydroxyethyl)cytidin | 47068-39-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5'-O-(2-Hydroxyethyl)cytidin
• 英文别名: O^5'-(2-hydroxy-ethyl)-cytidine；cytidine glycol；4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(2-hydroxyethoxymethyl)oxolan-2-yl]pyrimidin-2-one
• CAS: 47068-39-3
• 化学式: C₁₁H₁₇N₃O₆
• 分子量: 287.272
• InChiKey: RUNNMUQDJAPJLC-PEBGCTIMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing
  申请人：DARWIN MOLECULAR CORPORATION

  公开号：EP1004675A2

  公开（公告）日：2000-05-31

  Methods and compositions related to HIV are disclosed. Using the methods of the present invention, nucleoside analogs may be screened for the ability to be incorporated by reverse transcriptase of human immunodeficiency virus ("HIV RT") and cause incorrect base pairing. Progressive mutation of the virus by such nucleoside analogs renders it non-viable.

  本发明公开了与艾滋病毒有关的方法和组合物。使用本发明的方法，可以筛选出核苷类似物，以确定其是否能被人类免疫缺陷病毒（"HIV RT"）的逆转录酶结合，并导致不正确的碱基配对。这种核苷类似物可使病毒发生渐进变异，从而使其丧失生存能力。
• PCSK9 iRNA compositions and methods of use thereof
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US10125369B2

  公开（公告）日：2018-11-13

  The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.

  本发明涉及靶向 PCSK9 基因的 RNAi 制剂，例如双链 RNAi 制剂，以及使用这种 RNAi 制剂抑制 PCSK9 表达的方法和治疗血脂紊乱（如高脂血症）患者的方法。
• Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US10231988B2

  公开（公告）日：2019-03-19

  The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.

  本发明涉及靶向Patatin-Like Phospholipase Domain Containing 3 (PNPLA3)基因的RNAi制剂，例如双链RNAi制剂，以及使用这种RNAi制剂抑制PNPLA3基因表达的方法和治疗患有非酒精性脂肪肝（NAFLD）和/或PNPLA3相关疾病的受试者的方法。
• Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US10208307B2

  公开（公告）日：2019-02-19

  The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

  本发明提供了靶向转甲状腺素（TTR）基因的 iRNA 制剂，如双链 iRNA 制剂，以及使用这种 iRNA 制剂治疗或预防 TTR 相关疾病的方法。
• Angiotensinogen (AGT) iRNA compositions and methods of use thereof
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US10238749B2

  公开（公告）日：2019-03-26

  The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

  本发明涉及靶向血管紧张素原（AGT）基因的RNAi制剂，如双链RNAi制剂，以及使用这种RNAi制剂抑制AGT表达的方法和治疗AGT相关疾病（如高血压）患者的方法。